Therefore, it is reasonable to suggest that miR-21 or the TGF-β1-miR-21-PTEN-Akt axis may potentially developed as targets for clinical therapy of CRSwNP. This evidence concerns the gene TGFB1 and chronic rhinosinusitis with nasal polyps.